drugset / Trial / NCT02534363

Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up

NCT02534363

RandomizedParallel-groupOpen-labelTreatment

Summary

Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence daily functioning. Differences among antipsychotics in terms of cognitive effectiveness have turned out to be a topic of increasing research interest. The initially postulated superior neurocognitive effectiveness of second-generation antipsychotics (SGAs) compared to first-generation antipsychotics (FGAs) is currently under debate. Long-term studies would be of great value to evaluate the differential benefits exerted by antipsychotic drugs on cognitive performance. The aim of this study is to investigate the cognitive effects of aripiprazole, quetiapine and ziprasidone in first-episode psychosis at 1 year.

Timeline

Start
2005-10
Primary completion
2011-01
Completion
2013-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aripiprazole Other / unclassified 5 mg Oral
Comparator Aripiprazole Other / unclassified 30 mg Oral
Comparator Quetiapine Small molecule 100 mg Oral
Comparator Quetiapine Small molecule 600 mg Oral
Comparator Ziprasidone Small molecule 40 mg Oral
Comparator Ziprasidone Small molecule 160 mg Oral

Indications